An erectile dysfunction drug could treat Alzheimer's
AI Image

An erectile dysfunction drug could treat Alzheimer's

New York Post • • business

Key Points:

  • New research suggests that AR1001, a drug containing a lower dose of mirodenafil (an erectile dysfunction treatment used in Korea), may slow cognitive decline in Alzheimer's patients by 31%, particularly in those not on standard Alzheimer's medications.
  • AR1001 and sildenafil (Viagra) are both PDE5 inhibitors that improve blood flow by regulating cGMP, with potential benefits in enhancing brain blood flow and reducing Alzheimer's-related damage.
  • Mirodenafil is approved for erectile dysfunction in Korea but not yet FDA approved in the US; AR1001 is currently in phase 3 clinical trials for Alzheimer's and could apply for FDA approval by 2027.
  • Unlike existing Alzheimer's treatments like Donanemab and Lecanemab, which require IV infusions, AR1001 offers a convenient once-a-day oral pill option aimed at slowing disease progression in early-stage Alzheimer's patients.
  • Researchers observed that AR1001 may help preserve molecules crucial for brain cell communication, supporting its potential effectiveness in slowing Alzheimer's progression and expanding treatment options.

Trending Business

Trending Technology

Trending Health